ATBPF:OTC-Antibe Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 3.04

Change

+0.07 (+2.46)%

Market Cap

USD 0.15B

Volume

9.64K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-4.69 (-5.55%)

USD201.45B 28.21 3.25
CSLLY CSL Limited

-0.84 (-0.73%)

USD104.80B 39.33 31.42
CMXHF CSL Limited

+0.83 (+0.37%)

USD103.06B 38.69 31.42
GNMSF Genmab A/S

-16.18 (-3.66%)

USD29.30B 31.99 3.71
SBHMY Sino Biopharmaceutical Limited

N/A

USD20.76B 34.39 2.71
UCBJY UCB SA

-0.46 (-0.90%)

USD19.60B 22.41 16.19
UCBJF UCB SA

N/A

USD19.60B 21.15 16.19
SBMFF Sino Biopharmaceutical Limited

N/A

USD18.86B 31.25 2.84
PPTDF PeptiDream Inc

N/A

USD6.11B 121.49 0.72
OBMP Theralink Technologies, Inc

N/A

USD5.56B 0.76 N/A

ETFs Containing ATBPF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.84% 39% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.84% 38% F 26% F
Trailing 12 Months  
Capital Gain -9.43% 30% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.43% 29% F 16% F
Trailing 5 Years  
Capital Gain 213.71% 79% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 213.71% 79% C+ 76% C
Average Annual (5 Year Horizon)  
Capital Gain 44.86% 60% D- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.86% 59% F 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 90.57% 47% F 35% F
Risk Adjusted Return 49.54% 79% C+ 77% C+
Market Capitalization 0.15B 75% C 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.18 34% F 14% F
Price / Cash Flow Ratio -12.92 70% C- 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -216.96% 24% F 6% F
Return on Invested Capital -223.21% 9% F 4% F
Return on Assets -76.38% 36% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.05 79% C+ 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector